Safety and tolerability Of Lysyl OxidAse InhibitoR (LOX) In the amelioration of acute and established scAr: a single centre Phase I study

Project Details

StatusActive
Effective start/end date6/11/206/12/21

Funding

  • Pharmaxis Ltd: AUD623,663.00
  • Pharmaxis Ltd: AUD76,197.00